TTIL Trial on Alzheimer’s Aggression and Agitation Treatment Now Fully Enrolled

TTIL Trial on Alzheimer’s Aggression and Agitation Treatment Now Fully Enrolled
Transition TherapeuticsThe Irish subsidiary of biopharmaceutical company Transition Therapeutics Inc. has finished patient enrollment for its phase 2 clinical study to assess a novel therapy for mild, moderate and severe Alzheimer's disease. Transition Therapeutics Ireland Limited (TTIL) will now evaluate the neuropsychiatric drug candidate ELND005, expecting it to reduce both agitation and aggression. TTIL is going to conduct the phase 2 randomized, double-blind, placebo-controlled Harmony AD clinical study in order to assess the efficacy, safety and tolerability of the drug ELND005 across 12 weeks of therapy. The study will include 350 patients who suffer from mild to severe Alzheimer's and experience at least moderate agitation or aggression, according to a press release from the company. The Harmony AD Study will take place 
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *